نتایج جستجو برای: gnrha long protocol

تعداد نتایج: 1006411  

Journal: :acta medica iranica 0
l. safdarian f. soltani mohammadi e. rahimi

there is a challenging debate on the effect of premature luteinization on the clinical outcome of ‘controlled ovarian hyperstimulation' (coh) using long ‘gonadotropin-releasing hormone agonist' (gnrha) cycles. premature luteinization is defined as late follicular progesterone/estradiol ratio more than 1 on the day of human chorionic gonadotropin (hcg) administration. we carried out a retrospect...

Journal: :Human reproduction 2000
R M Janssens C B Lambalk J P Vermeiden R Schats J M Bernards L T Rekers-Mombarg J Schoemaker

Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the lowest possible dose of GnRHa should be used. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study t...

Journal: :American journal of physiology. Endocrinology and metabolism 2004
Xiaoping Luo Li Ding Nasser Chegini

Gonadotropin-releasing hormone analog (GnRHa) is used for medical management of endometriosis and premature luteinizing hormone surge during controlled ovarian stimulation. Human endometrium expresses GnRH receptors, and GnRHa alters the expression of transforming growth factor-beta (TGF-beta) and receptors in endometrial cells. Because the diverse biological actions of GnRHa and TGF-beta are m...

2004
Xiaoping Luo Li Ding Nasser Chegini

Luo, Xiaoping, Li Ding, and Nasser Chegini. Gonadotropinreleasing hormone and TGFactivate MAP kinase and differentially regulate fibronectin expression in endometrial epithelial and stromal cells. Am J Physiol Endocrinol Metab 287: E991–E1001, 2004. First published July 20, 2004; doi:10.1152/ajpendo.00200.2004.—Gonadotropin-releasing hormone analog (GnRHa) is used for medical management of endo...

2014
Kathrine Leth-Moller Sandra Hammer Jagd Peter Humaidan

The luteal phase of all stimulated in vitro fertilization/intra-cytoplasmic sperm injection (IVF/ICSI) cycles is disrupted, which makes luteal phase support (LPS) mandatory. The cause of the disruption is thought to be the multifollicular development achieved during ovarian stimulation which results in supraphysiological concentrations of steroids se- creted by a high number of corpora lutea du...

2011
Evangelos G Papanikolaou Peter Humaidan Nikos Polyzos Sofia Kalantaridou Sahar Kol Claudio Benadiva Herman Tournaye Basil Tarlatzis

Ovarian hyperstimulation syndrome (OHSS) still remains a life-threatening complication of in vitro fertilization treatment (IVF), keeping patients and especially those, who previously experienced OHSS, from attempting infertility treatment and childbearing. The recent implementation of four new modalities: the GnRH antagonist protocol, GnRH agonist (GnRHa) triggering of ovulation, blastocyst tr...

Journal: :Reproduction, nutrition, development 2001
S Cseh J Corselli P Chan L Bailey

The objective of this study was to investigate whether baboon females respond to an ovarian stimulation protocol incorporating pituitary suppression with a GnRH agonist (GnRHa) and highly purified human FSH (hphFSH) with follicular development and oocyte maturation. An ovulation induction protocol was applied to 5 adult female baboons with a history of regular menstrual cycles (33-34 days). A l...

Journal: :Human reproduction 1999
P Moreira H Saito T Kaneko T Saito K Nakahara M Hiroi

Many researchers have discussed fecundity on a per patient or per ovarian follicle basis. In contrast, this study was undertaken on a per ovary basis, and tests the hypothesis that there is a relationship between the fecundity of the bilateral ovaries in an individual patient and the incidence of apoptotic granulosa cells. The two ovaries of 10 women undergoing ovulation induction for in-vitro ...

Journal: :Circulation 1998
S F Yim T K Lau D S Sahota T K Chung A M Chang C J Haines

BACKGROUND Gonadotropin-releasing hormone agonists (GnRHas) are a group of drugs that with long-term use induce a pseudomenopausal state in which estrogen production is suppressed. They are commonly used in the treatment of sex steroid-dependent conditions. "Add-back" hormone replacement therapy is used to prevent menopause-like symptoms and bone loss during GnRHa treatment, but it is also reco...

2017
D. Hough M. Bellingham I.R.H. Haraldsen M. McLaughlin M. Rennie J.E. Robinson A.K. Solbakk N.P. Evans

Chronic gonadotropin-releasing hormone agonist (GnRHa) is used therapeutically to block activity within the reproductive axis through down-regulation of GnRH receptors within the pituitary gland. GnRH receptors are also expressed in non-reproductive tissues, including areas of the brain such as the hippocampus and amygdala. The impact of long-term GnRHa-treatment on hippocampus-dependent cognit...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید